

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
CENTERS FOR DISEASE CONTROL  
NATIONAL INSTITUTE FOR OCCUPATIONAL  
SAFETY AND HEALTH

+ + + + +

ADVISORY BOARD ON RADIATION AND  
WORKER HEALTH

+ + + + +

DOSE RECONSTRUCTION REVIEW METHODS WORK GROUP

+ + + + +

THURSDAY  
NOVEMBER 5, 2015

+ + + + +

The Work Group convened via teleconference at 10:00 a.m. Eastern Time, James M. Melius, Chairman, presiding.

PRESENT:

JAMES M. MELIUS, Chairman  
JOSIE BEACH, Member  
DAVID KOTELCHUCK, Member  
DAVID B. RICHARDSON, Member  
PAUL L. ZIEMER, Member

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

This transcript of the Advisory Board on Radiation and Worker Health, Dose Reconstruction Review Methods, has been reviewed for concerns under the Privacy Act (5 U.S.C. § 552a) and personally identifiable information has been redacted as necessary. The transcript, however, has not been reviewed and certified by the Chair of the Dose Reconstruction Subcommittee accuracy at this time. The reader should be cautioned that this transcript is for information only and is subject to change.

2

ALSO PRESENT:

TED KATZ, Designated Federal Official  
KATHY BEHLING, SC&A  
RON BUCHANAN, SC&A  
GRADY CALHOUN, DCAS  
DOUG FARVER, SC&A  
ROSE GOGLIOTTI, SC&A  
ED MAHER, ORAU Team  
DAN MCKEEL  
BETH ROLFES, ORAU Team  
MUTTY SHARFI, ORAU Team  
SCOTT SIEBERT, ORAU Team  
JOHN STIVER, SC&A

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

(202) 234-4433

[www.nealrgross.com](http://www.nealrgross.com)

This transcript of the Advisory Board on Radiation and Worker Health, Dose Reconstruction Review Methods, has been reviewed for concerns under the Privacy Act (5 U.S.C. § 552a) and personally identifiable information has been redacted as necessary. The transcript, however, has not been reviewed and certified by the Chair of the Dose Reconstruction Subcommittee accuracy at this time. The reader should be cautioned that this transcript is for information only and is subject to change.

C O N T E N T S

	<u>Page</u>
Welcome and Roll Call .....	4
Brief Overview of SC&A Review .....	11
Conclusions and Recommendations of Review .....	21
Dose Reconstruction Findings Statistics (SC&A report) .....	27
Possible Paths forward for Individual Case Reviews .....	75
Plans for November Board Meeting Discussion .....	85
Adjourn	

1 P-R-O-C-E-E-D-I-N-G-S

2 10:02 a.m.

3 MR. KATZ: Okay. Welcome, everyone.

4 This is the Advisory Board on Radiation and Worker  
5 Health, Dose Reconstruction Review Methods Work  
6 Group.

7 And we're meeting today, have Board  
8 Members, we have all five Work Group Members,  
9 including the Chair on the line already. And no  
10 conflict of interest matters to discuss. I don't  
11 think we need to run through that.

12 There's an agenda for today. It's  
13 posted. It's very simple. It's posted on the  
14 website under today's Board section. And I'm sure  
15 Jim will address that.

16 And otherwise, just please, everybody,  
17 mute your phones. Press \*6 to mute your phone if  
18 you don't have a mute button, and \*6 to take your  
19 phone off of mute.

20 And please, nobody put the call on hold,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 but hang up and dial back in if you have to leave  
2 the call for a bit.

3 And Jim, it's your meeting.

4 CHAIRMAN MELIUS: Okay. Thank you.  
5 And welcome, everybody from the Work Group. And  
6 otherwise, so forth and now we all got a long report  
7 from SC&A just recently.

8 So -- but I don't think we'll be  
9 discussing that in detail. I mentioned in an email  
10 to you that I think it's more of a background  
11 support document or a reference document that we  
12 can utilize as we go forward in terms of thinking  
13 about how we -- to what extent we would modify how  
14 we do the dose reconstruction reviews.

15 And then I think Ted had also sent out  
16 some of the documentation statistics from the Dose  
17 Reconstruction Review Committee's preparation for  
18 their upcoming report on their activities over  
19 time. So, it's just a lot of summary statistics  
20 on what the findings have been and so forth on that.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1                   And I think, I'm pretty sure  
2                   everybody's gotten both of those. I just want to  
3                   give anybody time if there's questions you have or  
4                   other documentation that you think would be helpful  
5                   to have going forward.

6                   We can come back to this later. But I  
7                   thought we should at least talk about it somewhat  
8                   now.

9                   MR. KATZ: While you're thinking about  
10                  that, I just realized that I didn't ask about Agency  
11                  members and staff and so on for participation.

12                  MEMBER ZIEMER: I was going to ask if  
13                  you had done a roll call.

14                  MR. KATZ: So I think we should that,  
15                  please. My apologies, but --

16                  CHAIRMAN MELIUS: Okay, then.

17                  (Roll call.)

18                  MR. KATZ: Okay, very good. Sorry.  
19                  And now back to Jim's question.

20                  CHAIRMAN MELIUS: Yes. Can you replay

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 the tape, then, so I don't have to repeat? So,  
2 anyway, that's the documentation.

3 I just would indicate for people that  
4 are not part of the Board or the Work Group, a lot  
5 of this is not sort of public information. So,  
6 these reports are not generally available at this  
7 point in time.

8 And for those of you on the Board, to  
9 the extent we are -- I don't think we're going to  
10 discuss these in any detail. But to the extent  
11 that we do, it's just reminding that there is sort  
12 of -- we have to be careful because there is Privacy  
13 Act information, covered information that's in  
14 particularly the more recent SC&A report. At  
15 least as I read some of the tables and so forth.  
16 Do that, so be cognizant of that. Does anybody  
17 have questions on the recent SC&A report, any of  
18 the Board Members?

19 MEMBER KOTELCHUCK: This is Dave. I'm  
20 wondering which one's your -- which one you're

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 referring to when you say recent SC&A Report.

2 CHAIRMAN MELIUS: That's the analysis  
3 of the 19th and 21st set of Dose Reconstruction  
4 Reviews.

5 MEMBER KOTELCHUCK: I've been out of  
6 town at a conference for a few days. When did that  
7 come in?

8 CHAIRMAN MELIUS: Late Thursday of  
9 last week.

10 MEMBER KOTELCHUCK: Aha. Okay. Let  
11 me -- I have not read that.

12 CHAIRMAN MELIUS: And that's why I  
13 wasn't expecting people to have, given its length.  
14 And it's -- and the time involved.

15 MEMBER KOTELCHUCK: Okay.

16 CHAIRMAN MELIUS: But again, it's more  
17 of a reference, you know, supporting document. I  
18 think it's -- I found it to be very helpful in sort  
19 of, it sort of establishes sort of the extent of  
20 how dynamic this program is in capturing what's --

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1       you know, we're doing dose reconstructions that  
2       have been completed.

3                   There's some lag from the time that they  
4       are completed before the time that we review them.  
5       Or SC&A review, you know, the whole process that  
6       the Dose Reconstruction Review Committee goes  
7       through.

8                   And during that time period -- and it  
9       actually sort of goes back to the selection of the  
10      cases up until the time we go through the review  
11      process. You know, changes take place. The SECs  
12      may be granted. Site Profiles change.  
13      Procedures change and so forth.

14                  And that happens, you know, on a sort  
15      of a continual basis. And so, I think trying to  
16      understand that. So, we may be, you know, doing  
17      an individual dose reconstruction review and  
18      actually the methods may be, you know, by the time  
19      that we review it, those methods may be different.

20                  MEMBER KOTELCHUCK: Right.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1                   CHAIRMAN MELIUS:   How different and  
2                   what changes or, you know, processes in place.  But  
3                   it's still -- doesn't mean that -- I mean, I think  
4                   it's just helpful to our understanding of this  
5                   whole process.

6                   This program has always been very  
7                   dynamic in the sense that rather than having a fixed  
8                   set of review criteria, those review criteria are  
9                   updated as more data becomes available or as we  
10                  refine the procedures that are being used to do the  
11                  dose reconstructions.

12                  MS. BEHLING:   Excuse me, Dr. Melius,  
13                  this is Kathy Behling.  I'm wondering, would the  
14                  -- or would the Work Group benefit from just a very  
15                  brief synopsis of this report?  I know it's  
16                  lengthy.

17                  But perhaps we could just focus your  
18                  attention on some of the conclusions.  What we, you  
19                  know, what we did.  A reminder as to what we did  
20                  and just some basic conclusions.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1                   So, that when you go through this, it  
2                   sort of focuses your attention. Do you think that  
3                   that's worth doing today? Because I think either  
4                   Rose or myself could do a very brief overview if  
5                   you're interested.

6                   CHAIRMAN MELIUS: I mean, it's really  
7                   up to the other Board Members.

8                   MEMBER BEACH: Jim, this is Josie.  
9                   I've glanced through it. I haven't had a whole lot  
10                  of time. But I think just a brief overview would  
11                  be helpful for me.

12                  CHAIRMAN MELIUS: Okay. But I would  
13                  emphasize on the brief.

14                  MEMBER BEACH: Brief. Yes, I was  
15                  thinking brief.

16                  CHAIRMAN MELIUS: Okay. So Rose, if  
17                  you or Kathy want to go ahead.

18                  MS. GOGLIOTTI: Yes, absolutely. So,  
19                  this review we focused on the 19th and 21st sets.  
20                  So there's 60 cases total in these sets.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1                   And we set out to answer some very  
2           specific questions on how individual dose  
3           reconstruction cases were impacted by ongoing  
4           Board activities, specifically SEC Class  
5           implications, procedure revisions that have  
6           happened since the dose reconstruction was  
7           completed, and ongoing issues resolutions.

8                   So, for SEC Class impacts, we looked at  
9           cases and answered the questions. Specifically  
10          was the case covered by an SEC? Was an SEC issued  
11          prior or subsequent to the case being reviewed?  
12          And if it was subsequent, would the review have --  
13          significantly be affected by the SEC? Did our  
14          review identify SEC issues? And did our review  
15          identify other potentially SEC issues that were not  
16          in the actual SEC Class?

17                   And from the SEC impacts standpoint,  
18          most of our cases did have an SEC that impacted them  
19          in some way, shape or form. I believe 50 of the  
20          60 cases had an SEC Class.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1                   But only six of those cases were  
2                   compensated as a result of the SEC. So, they had  
3                   a presumptive cancer and dose reconstruction was  
4                   warranted because they had non-presumptive cancers  
5                   as well.

6                   But from those cases, only four had SEC  
7                   Classes added that impacted them subsequent to the  
8                   dose reconstruction being completed. And of those  
9                   four, two cases were significantly impacted by an  
10                  SEC.

11                  So, they did result in compensation as  
12                  a result of the subsequent SEC. The remaining two  
13                  cases, one had a PoC greater than 50 percent for  
14                  the SEC Class, so it wouldn't be impacted by the  
15                  SEC. And the other was already compensated based  
16                  on a different SEC Class.

17                  For references, revisions, we looked  
18                  at, was a significant method in dose reconstruction  
19                  updated since the dose reconstruction was  
20                  completed? Would that impact -- or would that

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 update have a significant impact on the case? And  
2 did our review identify a need for that procedure  
3 to be updated?

4 And in this case, we found most cases  
5 did have a few. I think 35 cases had a reference  
6 that was updated since it was completed. But only  
7 24 of those had a reference that was updated that  
8 impacted dose.

9 And this is more of a qualitative than  
10 a quantitative analysis. So we didn't go in and  
11 recalculate doses to see the update, if it affected  
12 the PoC in a significant way.

13 But I will say that it was a little bit  
14 complicated with OTIB-54 that's been revised five  
15 times in -- since these cases were complete. So  
16 it's a little difficult to quantify the extent of  
17 a change when there's so many revisions happening  
18 in such a short period of time.

19 And also OTIB-52, which is the  
20 construction trade workers, and that was revised

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 to include subcontractors. And so, that wouldn't  
2 have been cited if they had erroneously excluded  
3 subcontractors in the past. So, it's really  
4 difficult to quantify if that particular change  
5 would have impacted cases.

6 And we do have a list of the procedures  
7 that were updated and used in this case set. And  
8 then we also looked at references that were, have  
9 we reviewed the references? And is there ongoing  
10 issues resolution that could impact these  
11 individual cases?

12 And so to do those we broke it up into  
13 two categories. The Site Profile findings and  
14 everything else.

15 And that's just because the Site  
16 Profiles are typically drawn-out processes. And  
17 there are numerous considerations. And it's much  
18 more complicated than some of our procedure  
19 reviews.

20 So were broke that down and looked at

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 just Site Profiles. And we also actually pulled  
2 in SEC ER review findings because they are  
3 integrated and related to the TBD methodologies.

4 And in these cases we had 33 facilities  
5 represented of the over 300 facilities that are  
6 covered under EEOICPA. And seven of those  
7 facilities did not have formal Site Profiles.

8 And the remaining 26 facilities that  
9 did have Site Profiles, all but Pacific Northwest  
10 National Labs have been reviewed. And 22 of those  
11 reviews still have open issues.

12 So, 72 percent of cases that were  
13 reviewed in this subset, which is not a random  
14 sampling, did have ongoing issues resolution that  
15 could impact these cases.

16 We also looked at the non-TBD  
17 methodologies. And we had 34 unique NIOSH  
18 guidance documents that were not TBDs that were  
19 used in these, and the vast majority of these have  
20 been reviewed by SC&A. And the vast majority do

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1 not have open findings that impact these cases.

2 We did identify two that have not been  
3 reviewed: OTIB-70 and OTIB-64. And 64 actually a  
4 subsequent -- or a -- the document that it  
5 supersedes was reviewed and has no open findings.

6 So, it's really one full document has  
7 not been reviewed. And that is site-specific, I  
8 believe.

9 And we also had six procedures that have  
10 open issues that we determined could potentially  
11 impact these cases.

12 MS. BEHLING: Excuse me, Rose. I'm  
13 going to interrupt you for just one second at this  
14 juncture.

15 The other thing that was not reviewed  
16 and we didn't go into a lot of detail in the report,  
17 is the templates. Again, this is the dose  
18 methodology that we have now discovered is embedded  
19 into the Dose Reconstruction Reports.

20 And I believe NIOSH has put together a

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 listing of all of the sites that actually have  
2 templates and still think that's something that,  
3 you know, has not been reviewed by SC&A. And  
4 there's a lot of data in those templates.

5 So, it's something we may still want to  
6 -- the Board may want to consider having us look  
7 at. Sorry, Rose.

8 MS. GOGLIOTTI: That's all right.  
9 Thank you, Kathy. That is actually important.

10 And then in the course of doing this  
11 evaluation, we did also draw some broader  
12 conclusions and recommendations, which is outlined  
13 in Section 1.4 of this report. And actually I  
14 think that would be very meaningful to this report.

15 I can go through those if you'd like.

16 CHAIRMAN MELIUS: Yes. Go ahead.

17 MEMBER BEACH: Oh, Jim, can I ask a  
18 question of Kathy?

19 CHAIRMAN MELIUS: Yes, sure.

20 MEMBER BEACH: You said that the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1       template, you had a list of the templates from  
2       NIOSH. Did we get those?

3                   MS. BEHLING:       I was under the  
4       impression that -- Ted, can you correct me here?  
5       I thought that NIOSH had provided a list of the  
6       facilities where there is a template like the Grand  
7       Junction and Westinghouse Nuclear Fuels.

8                   And has that list been provided?

9                   MR. KATZ:       Well, I definitely  
10      distributed it. I'm not sure how widely. Whether  
11      just to the DR Work Group or what have you.

12                   But I can go check my records and see.

13                   MEMBER BEACH:   Okay. Thanks.

14                   MS. BEHLING:   Okay. I wasn't sure if  
15      it was going to be this Work Group that would make  
16      the decision as to which templates are going to be  
17      reviewed, or if that's a full Board discussion. I  
18      don't know.

19                   CHAIRMAN MELIUS:   That's a full Board  
20      discussion.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 MS. BEHLING: Okay. Rose, I think you  
2 can go ahead. Because I think it's important that  
3 we get a, you know, that the recommendations and  
4 the conclusions be discussed.

5 MS. GOGLIOTTI: I completely agree.  
6 Well, our first recommendation, we really strongly  
7 recommend that the Site Profile and SEC Position  
8 Evaluation Report Issues Resolution starts to  
9 become documented on the BRS similar to how the  
10 Procedures Subcommittee documents their findings.

11 This was a monumental task going in and  
12 figuring out which TBD findings are still open and  
13 relevant. Many of these TBDs were done back, some  
14 of them as early as 2005.

15 And they still have open findings. But  
16 tracking down to identify that these findings were  
17 still open was very, very difficult.

18 And we cannot stress enough how much  
19 Subcommittees would benefit from putting their  
20 findings in a centralized location so you don't

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 have to dig through mountains of documents to  
2 identify what finding is still open and what is  
3 closed.

4 We also felt that our TBD and SEC  
5 reviews, we need a standardized and consistent  
6 numbering format for these. When we were going  
7 through findings, we noticed a lot of times Work  
8 Groups would renumber their findings midway  
9 through, which is very difficult to track a finding  
10 if the numbers are changing between documents.

11 We also noted that we would like to see  
12 an update to Section 1.3 of our DR Report. And if  
13 you remember back to our DR Report, that's where  
14 we document TBD reviews that were completed, and  
15 if there were findings associated with the TBD  
16 review that could impact the case.

17 And when we first started doing DR  
18 Reviews, that made sense. It was meaningful. We  
19 could look back and see.

20 But since then, things have changed.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 Ten years down the road, it's very difficult for  
2 our reviewers to know which issues are still open,  
3 which are relevant, if any of these issues have been  
4 addressed.

5 So, we stick to TBD reviews. But  
6 things have changed since then. Our DR reviews are  
7 typically not involved in issues resolution  
8 process for a site. So, we don't necessarily have  
9 access to the current status of ongoing issues  
10 resolutions or subsequent reviews that could  
11 actually impact the case.

12 So, we would recommend that either we  
13 need to commit to maintaining an up-to-date list  
14 of unresolved issues for each Work Group, or we need  
15 to move to the BRS with a more standardized system.

16 We also noted that the Procedures  
17 Subcommittee has done a really good job of  
18 capturing all of the references, but we would note  
19 that a lot of the documents that we reviewed were  
20 earlier revisions.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1                   And subsequent review -- or subsequent  
2 documents have been issued, and we think that the  
3 Procedures Subcommittee would benefit from  
4 investigating the changes that happened to these  
5 revisions and identifying when a substantial  
6 enough revision was made that may warrant us  
7 looking at the review again.

8                   We also noted that the majority of cases  
9 have unresolved TBD and SEC issues. And based on  
10 that observation, we suggest that the Board should  
11 prioritize resolving open issues, especially at  
12 the larger employment sites.

13                   And then I also just wanted to point out  
14 that this document focuses on unresolved issues.  
15 So, findings that are open or unresolved.

16                   We did not focus on findings that are  
17 in abeyance. And what that means at least on some  
18 Subcommittees would be that the finding has been  
19 resolved but not implemented and formally closed.

20                   So, those findings still have the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 potential to impact cases even though they are  
2 technically resolved in the Subcommittee levels.  
3 And those were our recommendations.

4 Are there any questions?

5 MS. BEHLING: And this is Kathy  
6 Behling. If I could just add one more note. As  
7 you see here, based on our conclusions or  
8 recommendations, is that it would benefit  
9 everyone, I think, if the BRS was being used more  
10 widely among all the Work Groups.

11 I think that this report really lays the  
12 foundation, for if the Work Groups decide to go in  
13 that direction, that we could assist them in  
14 updating the BRS. Because this report and all the  
15 effort that went into it would allow us to help  
16 those Work Groups to populate the BRS.

17 And it would also allow if we did it  
18 along with the Work Groups, and would allow for  
19 consistency and perhaps even consistency in  
20 numbering format.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1                   I realize there has been a lot of water  
2                   under the bridge. And there's been, I'm sure, some  
3                   of the Work Groups are a little bit hesitant to go  
4                   in that direction. But if we could just start  
5                   today and put in open findings. And in-progress  
6                   type findings today and move forward.

7                   I think that would be of a great benefit  
8                   not only to the Work Group, but to us as auditors  
9                   and for posterity, and making sure that we all keep  
10                  track of everything that has been done in this  
11                  extensive program.

12                  CHAIRMAN MELIUS: Any other questions?

13                  MEMBER ZIEMER: This is Ziemer. Jim,  
14                  I think there's certainly a number of these  
15                  recommendations that are beyond just Sets 19 and  
16                  21. They're gone and proper finishing.

17                  And clearly it's a little more  
18                  consideration. I'm wondering if there should be  
19                  a, you know, a comprehensive report on this kind  
20                  of issue.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 I don't know if it's Dose  
2 Reconstruction Work Group that should deal with it.  
3 It goes beyond their Work Group. I think it covers  
4 all of them. And that's an overall report to the  
5 Board that's been suggested actually would be  
6 appropriate.

7 CHAIRMAN MELIUS: Paul, I'm actually a  
8 little puzzled by the conclusion and  
9 recommendations. You know, aside from whether or  
10 not they're, you know, helpful or useful or  
11 whatever for the overall Board.

12 They seem to have nothing to do with the  
13 dose reconstruction methods.

14 MEMBER ZIEMER: Yes, it's interesting.

15 CHAIRMAN MELIUS: I mean, I was -- and  
16 I -- you know, I'm actually always puzzled when I'm  
17 doing individual dose reconstruction reviews.

18 I mean, some of these issues seemed to  
19 be, you know, sort of a lack of communication within  
20 SC&A on what's going on in the program, and what

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 else.

2 I mean, stuff that can be looked up on  
3 the website in, you know, two or three minutes  
4 doesn't seem to get done. And that now -- yes, I  
5 -- there may be a need for more systemization of  
6 what -- of review process for Site Profiles and so  
7 forth.

8 But I think we're trying to focus on  
9 dose reconstruction review methods, not, you know,  
10 something as broad as this. And I didn't find that  
11 part of the report particularly helpful for us in  
12 terms of our task today.

13 MEMBER ZIEMER: No, in fact, that's why  
14 I'm saying this sounds like it should be something  
15 as a separate report to the Board for those kinds  
16 of recommendations.

17 CHAIRMAN MELIUS: Yes. Yes.

18 MEMBER KOTELCHUCK: I agree.

19 CHAIRMAN MELIUS: Yes.

20 MS. GOGLIOTTI: Well, certainly this

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 report looked at how the dose reconstruction work  
2 is impacted by the work that is being done in other  
3 Subcommittees and other Work Groups. So, that's  
4 why we felt this was appropriate.

5 CHAIRMAN MELIUS: Well, that was the  
6 intent of the report was how it was affected. And  
7 to try to sort of benchmark the extent at which  
8 things were in process.

9 But, you know, your conclusions and  
10 recommendations seem to focus all on that document  
11 or technical document review process, not on dose  
12 reconstruction methods and so forth.

13 And, you know, again, I'm not  
14 disputing, you know, particularly your -- the  
15 recommendations or whatever. Or findings. But  
16 that part of it wasn't what we were expecting.  
17 That's all I -- and I think there are, for some of  
18 these issues, there are other approaches that need  
19 to be considered in terms of what we're doing and  
20 so forth.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 Any other questions or comments on that  
2 part?

3 (No response.)

4 CHAIRMAN MELIUS: Okay. So, let's go  
5 back to individual case reviews and methodologies.  
6 And I sent a short email out to the Work Group  
7 Members to sort of -- at least my thinking about  
8 how we should approach this and so forth.

9 And at least in terms of different parts  
10 or different considerations for modifying the Work  
11 Group -- the Dose Reconstruction Review process.  
12 And that's not in detail.

13 And I think all these we've discussed  
14 previously. But maybe if we go through them one  
15 at a time, it gives us some organization to this  
16 meeting.

17 So, I think what we have talked about  
18 is, you know, one, you know, continuing the  
19 current, you know, review process. And -- but  
20 with, in order to make it more efficient, do we only

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 focus on like the positive findings?

2 And then sort of separately from that,  
3 do we only -- do we change our selection procedures  
4 in terms of how we select cases in some way to make  
5 them, you know, sort of improve that process or --  
6 and we have, I think, done that continually in the  
7 Dose Reconstruction Review Committee in terms of  
8 trying to focus on sites that haven't been  
9 evaluated before, or based on Probability of  
10 Causation, or, you know, other issues like that.

11 But I think the key one is I'd like to  
12 get back to it for some discussion is the issue of,  
13 do we want to modify the process in a way that is  
14 -- that we would provide more focus on just the --  
15 sort of the positive findings that SC&A may have  
16 when they review an individual case as it sort of  
17 goes through the resolution process.

18 MEMBER KOTELCHUCK: Jim?

19 CHAIRMAN MELIUS: Yes?

20 MEMBER KOTELCHUCK: I mean, I found the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 SC&A proposal -- and I don't have the date on it  
2 -- of suggesting that we go through this by having  
3 more involvement with SC&A and NIOSH ORAU, before  
4 the Subcommittee meeting, and that we get sent a  
5 list of cases, that there seems to be pretty much  
6 agreement. And just check on those at the  
7 Committee before we get to the Committee meeting.

8 And that will allow the Committee to  
9 focus on problems, disagreements. And that seemed  
10 to me to be a very good way of speeding up our  
11 process, and therefore allowing us to review a  
12 greater proportion of cases. I don't know how  
13 great a proportion, how great an increase it would  
14 be because we haven't tried it.

15 But it seemed to me a good starting  
16 point for modifying the process and making it more  
17 useful and making the meetings more useful.

18 MS. BEHLING: This is Kathy Behling.  
19 If I could interject, that was a memo that I sent  
20 out on July 15, 2015. And the subject was approach

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 to expediting the Dose Reconstruction Project.

2 MEMBER KOTELCHUCK: That's it. Yes.  
3 Right.

4 MS. BEHLING: On July 15, I put  
5 together a memo. And as you're referring to type,  
6 we classified them as Type I type findings that  
7 perhaps will only require minimal discussion. And  
8 then a Type II finding which would be a more  
9 detailed discussion.

10 And we actually in that memo, I used an  
11 example of four different sites. There was a table  
12 in that memo where we looked at the Oak Ridge Site,  
13 the Paducah, Portsmouth and Savannah River Sites.

14 And we tried to put it in perspective,  
15 the number -- the total number of findings. How  
16 many are still open, what we would think might fall  
17 into this Type I and Type II classification.

18 We also included a table that we  
19 actually list the finding. We list the discussion  
20 between us and NIOSH, gave you an understanding of

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1 the ranking and the PoC for that particular  
2 finding.

3 And we were hoping that, before the  
4 meeting we could get this into your hands at least  
5 a week or whatever, you know, how much time you  
6 would need. So that you could go through this.

7 And then at the meeting, for those Type  
8 I findings, perhaps the Board Members can state,  
9 yes, we agree with all these. Or no, we want to  
10 have a further discussion on this particular  
11 finding.

12 And based on these four sites that I  
13 looked at, we estimated about 79 percent of the  
14 findings for those four sites, and 94 percent of  
15 the observations appear that they are not going to  
16 need a very lengthy discussion to close.

17 Obviously, that's your call. But if we  
18 provide you with that summary table before the  
19 meeting, it would be something I think that would  
20 certainly help to expedite getting through --

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 closing hopefully some of these findings.

2 But all of this that I'm discussing is  
3 in a July 15 memo.

4 MEMBER KOTELCHUCK: Right. And that  
5 -- am I on?

6 CHAIRMAN MELIUS: You're on, Dave.

7 MEMBER KOTELCHUCK: Okay. That was a  
8 very useful memo. And I just simply, how much time  
9 we'd save and how many of them would be closed with  
10 minimal discussion, I'm not sure until we try it.

11 But certainly, it seems promising.  
12 And I also -- I've for a long time -- we had a  
13 discussion in the Subcommittee about observations.

14 And a number of us wanted just to not  
15 have any discussion at all. Several Members of the  
16 Subcommittee pointed out that, in fact,  
17 occasionally we change an observation to a finding,  
18 which is important.

19 And that there are more substantive  
20 matters behind the -- what appeared at first to be

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 an observation. So, this method that you're  
2 suggesting, that SC&A is suggesting, would allow  
3 us also to look at the observations. And, you  
4 know, essentially, I hope heartily discuss any of  
5 them. And you indicated you thought 94 percent of  
6 them would be closed.

7 That seems like a reasonable number,  
8 and that would save time. And even when we talk  
9 -- because when we talk now in the Subcommittee  
10 about the observations, people go through, you  
11 know, a detailed discussion, as is proper.

12 But it just takes time. And we are not  
13 going to -- we are not going -- generally, we're  
14 not going to take a position and just say so noted.  
15 Right? And move on.

16 So, it's a waste of valuable time for  
17 the discussion group, you know, during the  
18 conference -- a waste of time during the conference  
19 call.

20 So this seems to me -- now, we haven't

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 had a discussion in the Subcommittee. And Josie,  
2 correct me if I'm wrong. But I don't believe our  
3 Subcommittee has actually discussed this, whether  
4 we want to go ahead on this.

5 MEMBER BEACH: I thought we had a brief  
6 discussion on it. But, yes, I don't believe we've  
7 had anything --

8 MR. KATZ: No. This is Ted. I'm  
9 sorry, I think we felt this was in the purview of  
10 the Methods Group to talk about it.

11 MEMBER KOTELCHUCK: Okay. That  
12 sounds good. Okay. That's -- you're right. I  
13 think you're right.

14 MEMBER ZIEMER: Well, Ted and Jim, this  
15 is Ziemer. According to my notes from our June 22  
16 meeting, we discussed this quite a bit. I thought  
17 we had at least tentatively agreed to this kind of  
18 approach. I'm looking at my notes here and I have  
19 all those things down.

20 MR. KATZ: Paul, I think we did talk

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1       about it some. I'm quite sure we didn't come to  
2       any resolution on any of these changes -- possible  
3       changes.

4                   MEMBER ZIEMER: Right.

5                   MEMBER KOTELCHUCK: But you're right.  
6       I mean, this was mentioned. But, I mean, my  
7       feeling at this point is that we should move for  
8       resolution on it.

9                   If we have general good feelings about  
10      it, that is that it's a reasonable method -- and  
11      I would just ask that, you know, we approve in  
12      principle, and then let the Subcommittee decide,  
13      you know, some of the details.

14                  But the basic approach, I think my  
15      feeling is, I'm ready to say let's try it. You  
16      know, this is not a forever decision, and if we find  
17      after some experience that there are problematic  
18      aspects to it, we can change it.

19                  But this time, again, with Board  
20      approval.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1                   MEMBER BEACH: Yes, but I think we need  
2                   to send that memo forward to this group if it's  
3                   something you're suggesting. Because I don't  
4                   think everybody has it.

5                   MEMBER KOTELCHUCK: That may be. I  
6                   believe you may have come onto a Subcommittee since  
7                   -- did you come onto a Subcommittee since the memo  
8                   was --

9                   MEMBER BEACH: No, I was on a  
10                  Subcommittee.

11                  MEMBER KOTELCHUCK: I don't remember.

12                  MEMBER BEACH: I'm just having trouble  
13                  locating it.

14                  MEMBER KOTELCHUCK: Okay. I was  
15                  having trouble locating it, too. But that's my  
16                  problem. And once I have the date here, I have it,  
17                  of course.

18                  MEMBER BEACH: And it was --

19                  MS. GOGLIOTTI: It's a PA-cleared  
20                  document, so I can send it along.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 MEMBER KOTELCHUCK: Yes. Okay.

2 MEMBER BEACH: Thank you.

3 MS. BEHLING: I will also add -- this  
4 is Kathy Behling. That if you are --

5 CHAIRMAN MELIUS: Kathy, please, this  
6 is a Board Work Group discussion. And --

7 MS. BEHLING: I'm sorry, I was just  
8 going to say --

9 CHAIRMAN MELIUS: We'll ask for your  
10 input when we need it.

11 MS. BEHLING: Okay. I'm sorry. I was  
12 going to say SC&A could reference --

13 CHAIRMAN MELIUS: Thank you, Kathy.  
14 Please, we know that.

15 MEMBER KOTELCHUCK: Well, anyway, I  
16 would say let's go ahead -- from my own I would say,  
17 and as Chair of that Subcommittee, I would say let's  
18 adopt it. Let's formally agree to do so.

19 And then that would be, if you will,  
20 part of our report to the Secretary. In the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 section called -- after results, called future  
2 activities.

3 CHAIRMAN MELIUS: Well, I have some  
4 concerns about that.

5 MEMBER KOTELCHUCK: Okay.

6 CHAIRMAN MELIUS: And the concern is  
7 that the Board is charged with doing Dose  
8 Reconstruction Reviews, you know, not our  
9 contractor. And we're essentially turning over  
10 that function to our contractor if we're not  
11 reviewing the findings.

12 MEMBER KOTELCHUCK: Well, but we are  
13 reviewing the findings in that it's supposed to be  
14 sent to the Board a week before, and we are supposed  
15 to go through it.

16 Now, it's our responsibility as a  
17 Subcommittee to actually read through what they  
18 say. Now, if they just send things out and we do  
19 not examine it ourselves, then we are giving up our  
20 responsibility and our required responsibility.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1                   But my figure is that our people are  
2                   disciplined enough that the Subcommittee people  
3                   will read through carefully, and we can certainly  
4                   check that at the meetings that we have to make sure  
5                   everybody's really read it through carefully.

6                   CHAIRMAN MELIUS:   And give them a quiz,  
7                   Dave?

8                   MEMBER KOTELCHUCK:   Well, no.   But I  
9                   think --

10                  CHAIRMAN MELIUS:   You and Paul can take  
11                  turns writing.   You've had students for many  
12                  years.

13                  MEMBER KOTELCHUCK:   Right.

14                  CHAIRMAN MELIUS:   You can write out  
15                  the quiz.   But I guess I'm having a little bit of  
16                  trouble figuring out why having a memo is -- when  
17                  you're in the Board -- in a Subcommittee meeting,  
18                  you're telling me that people don't have the  
19                  discipline to go quickly through a -- what's called  
20                  a minor finding.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 MEMBER KOTELCHUCK: Well --

2 CHAIRMAN MELIUS: Well, let me finish,  
3 Dave, please.

4 MEMBER KOTELCHUCK: Sure.

5 CHAIRMAN MELIUS: But you're saying that  
6 if we shorten that in a memo and give them less  
7 information, you know, maybe they'll not feel the  
8 need to ask questions or talk about it.

9 And it seems sort of counterintuitive  
10 that that would happen. It seems to me that we're,  
11 you know, as I said, delegating our  
12 responsibilities to our contractor.

13 And without giving due diligence to  
14 what that responsibility is, which is to review  
15 and, you know, identify problems with the dose  
16 reconstruction, the individual dose  
17 reconstructions.

18 MEMBER KOTELCHUCK: Well, I certainly  
19 was concerned about that when I saw the memo, and  
20 thinking about it. But as we go through our

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1        Subcommittee meetings, the minute we review a case,  
2        people go through like ten or a dozen or so  
3        different, you know, the internal dose, the  
4        external dose, how we got it, how we calculated it.

5                    And in many cases that is -- that's not  
6        an issue and say, okay, I mean, you know, 10 out  
7        of the 12 points that they go through are not points  
8        in which there is disagreement.

9                    And at some deeper level though, we do  
10       give responsibility to the staff, the SC&A and  
11       NIOSH. We review, but we really don't as  
12       individual Board Members, we don't go through a  
13       calculation. Right?

14                    And so we are giving them major  
15       responsibility and we're overseeing them. So, I  
16       would say if the oversight -- if the time spent in  
17       the Committee meeting doesn't produce any useful  
18       -- puts a lot of words and time down and doesn't  
19       present much useful material, then I just feel as  
20       if -- I'm willing to give a certain amount of

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 greater responsibility to the two staffs.

2 Again, with the obligation that we go  
3 over it carefully on the Board. And no, I can't  
4 tell you -- I'm not going to give them a quiz  
5 obviously.

6 But I think the Board Members, knowing  
7 that they are giving up some degree of oversight,  
8 will certainly be careful. And I think will be  
9 honest enough and open enough to say, well, you  
10 know, I haven't reviewed this. I'm not, you know,  
11 I'm going to listen or something like that.

12 Because, obviously, if they haven't  
13 read and gone over the material, then it's not --  
14 their input is not -- the oversight that we should  
15 have is not there.

16 But I just find a lot of time is spent  
17 at the meetings on repetitive items where there's  
18 no disagreement because one goes through  
19 everything. Maybe we should.

20 CHAIRMAN MELIUS: Okay.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1                   MEMBER ZIEMER:     Could I make some  
2     additional observations?

3                   CHAIRMAN MELIUS:    Yes, please.

4                   MEMBER ZIEMER:    This is Ziemer. Well,  
5     one thing is that we need to remember there's a  
6     couple of parts to this.

7                   One is, a priori, before SC&A is ever  
8     involved, the Board is involved in -- and the  
9     Subcommittee -- involved in selection of cases.  
10    And I think, Jim, part of what you're asking is,  
11    should we modify that selection process in terms  
12    of either proportion of cases or what other  
13    criteria we may wish to include going forward? That  
14    this also includes whether we should increase  
15    numbers of blind reviews and that means we need to  
16    evaluate the value of the blind reviews. Are they  
17    giving us more information than the other ones that  
18    are -- that's important?

19                   So, there's a lot of issues. I think  
20    that we have to, in terms of this review process,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 just in case selection, clearly we're depending on  
2 the contractor to go through what I'll call the  
3 mechanics of dose reconstruction. Because a lot  
4 of it is sort of mechanical in the sense of the  
5 procedures are there. And they're going through  
6 and sort of checking against those procedures.  
7 And then preparing a report.

8 But we have an important consideration  
9 in the selection of what they do. And then it seems  
10 to me we need to be focusing a lot on consistency  
11 issues.

12 And we may need to give instructions to  
13 our contractor as to what we want to look at in terms  
14 of consistency. You know, are people in the same  
15 category, are the cases being handled in a  
16 consistent manner, that sort of thing.

17 The issue of what we do with the  
18 observations and so on, I think the Subcommittee,  
19 the Dose Reconstruction Subcommittee, as you  
20 suggest, they can come up with those very easily.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 And they can make that determination of what things  
2 they can go through quickly or not.

3 But certainly a lot of our  
4 responsibility starts at the front end in the  
5 selection of the cases.

6 CHAIRMAN MELIUS: No, I mean, I agree.  
7 And this part of the process, which is what's called  
8 the traditional or the old process has been -- I  
9 think it's question of, is there a way of making  
10 the resolution more efficient?

11 MEMBER ZIEMER: Yes.

12 CHAIRMAN MELIUS: But in some sense we  
13 have a check on SC&A because what gets flagged is  
14 when, you know, their calculation differs from  
15 NIOSH slash ORAU's calculation. You know on a --  
16 in that.

17 And usually at least my experience has  
18 been that they're very diligent at tracking down  
19 when there is a, you know, inconsistent finding.  
20 Now, I mean, what we always worry about is that

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1       they, you know, both NIOSH slash ORAU and SC&A get  
2       it wrong. But, usually, that's not going to be in  
3       the calculation per se but in some of the  
4       assumptions that go into the calculation, I would  
5       think and do that.

6                   MEMBER ZIEMER: Right.

7                   CHAIRMAN MELIUS: And usually that's  
8       -- when there is a discrepancy, that's what's that.  
9       It's sort of -- it's an error. Sort of not an error  
10      but a difference in interpretation on period.

11                   And then some just, you know, simple  
12      mistakes that are probably not very -- they're  
13      usually not very important in the larger scope of  
14      the dose reconstruction that's being done.

15                   Where somebody, you know, puts down the  
16      wrong month or includes an extra month or leaves  
17      off a month or that kind of thing. And based on,  
18      you know, just transcribing from the work records  
19      or there's a discrepancy in that.

20                   But it would seem to me rather than

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1       having a two-resolution process, so to speak, one,  
2       you know, without the Board involved, just SC&A and  
3       NIOSH; that we have, you know, we have one process.

4               And it's a question of how you manage  
5       that. Now, you know, a separate question is  
6       whether we want a way of sort of combining these,  
7       is that we, you know, have a process where we would  
8       only focus on positive findings, and we totally,  
9       you know -- or on major findings somehow defined.  
10       I think that would be, you know, a reasonable  
11       possibility.

12               But I still think you have to sort of  
13       mix that with sort of a complete review of the dose  
14       reconstruction process. Because, you know, there  
15       are, you know, people that have a very high  
16       Probability of Causation under 50 where, you know,  
17       a small change can make a difference. Not  
18       commonly. But, you know, it does occur. And I  
19       think we have some obligation to make sure that the  
20       overall process is going satisfactorily.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 I don't remember the details of the SC&A  
2 proposal. So, I may be mischaracterizing it. But  
3 I guess I just feel more comfortable at this point  
4 of, you know, modifying the Committee,  
5 Subcommittee process.

6 MEMBER KOTELCHUCK: Mm-hmm. I mean, I  
7 just feel as if we spend a lot of time needlessly  
8 on things where there's no disagreement.

9 Now, possibly it's a question of myself  
10 as Chair, simply ruling those same, let's not talk  
11 about those. Let's go to the major findings.

12 I mean, but once we review a case,  
13 typically we go over a number of -- most items in  
14 the calculation. We've always done that. And  
15 maybe we shouldn't. But I don't see, Jim, in what  
16 you're saying, I don't see what would be changed.  
17 And I am interested in changing and speeding up the  
18 process.

19 CHAIRMAN MELIUS: I think what -- and  
20 again, I don't fault you for your running the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 meeting. Because I don't think it was different  
2 than Mark. And you're our two Chairs.

3 MEMBER KOTELCHUCK: Right.

4 CHAIRMAN MELIUS: Paul's, I think,  
5 been on the Subcommittee since the beginning. You  
6 can comment.

7 And I'm not, you know, I understand that  
8 people in a Work Group or a call or a meeting,  
9 whatever, like to talk and spend time. But it  
10 seems -- and when we do the individual Board Member  
11 reviews prior to the Subcommittee, we go through  
12 it finding by finding.

13 And that's been, you know, done. I  
14 mean, we all when we're reviewing it, you know, the  
15 paperwork ahead of time we focus on positive  
16 findings and observations. Because that's most  
17 likely what's going to change.

18 But there is a process of at least the  
19 ones I do, where we go through them one at a time.  
20 But I think that we have a -- I think if, you know,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 the Subcommittee reaches an understanding that,  
2 you know, we're going to, you know, start with a  
3 positive finding so to speak, or a higher priority  
4 findings.

5 And then, you know, go through and when  
6 you get to the, you know, the lower priority, the  
7 negative findings, whatever you want to call them  
8 that you sort of group them. And does anybody have  
9 questions on them or concerns they want to raise.

10 MEMBER KOTELCHUCK: Yes.

11 CHAIRMAN MELIUS: So, to me that would  
12 be, you know, possibly more efficient, you know.  
13 I don't want to be overly optimistic because, you  
14 know.

15 MEMBER KOTELCHUCK: I will admit, and  
16 first by the way, I don't -- whatever we talk about,  
17 how the Subcommittee should go, I'm more than open  
18 to suggestions. Including suggestions that I  
19 change, modify things.

20 I am not at all feeling personally

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 threatened by suggestions by the Board of how we  
2 ought to function. Far from it.

3 But one of the things that has  
4 influenced me, and maybe overly so, and maybe  
5 inappropriately so. Is that we had originally  
6 said in our first Secretary's report that we were  
7 going to go over 2.5 percent of cases.

8 When I took over, we had a terrible  
9 backlog. We still do. We have a backlog. But  
10 we've been making progress on that.

11 And so I've always -- we did not even  
12 make -- we have not even reviewed SEC in the graphs  
13 that we have. We did not even review one percent  
14 of cases.

15 We have 0.86 percent of cases. So,  
16 there has been the feeling. I certainly have the  
17 feeling, and maybe have been overly influenced by  
18 that of feeling that we should be moving toward one  
19 percent and beyond.

20 If in fact, we are comfortable with one

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 percent and we -- then I'm not unhappy with our  
2 current process, personally not unhappy just as a  
3 Board Member and as the Chair.

4 But if we can speed it up or do things  
5 differently, obviously I'm more than open.

6 MEMBER ZIEMER: This is Ziemer. I  
7 have a comment on that if I may.

8 MEMBER KOTELCHUCK: Please.

9 CHAIRMAN MELIUS: Go ahead.

10 MEMBER ZIEMER: It seems to me that we  
11 may be at a point, and Jim, I don't know if it's  
12 this Review Committee that should do it or what.

13 But I think we have to ask ourselves a  
14 question on that. And that is the following. The  
15 original two and a half percent in a sense was  
16 somewhat arbitrary. I don't think we knew how much  
17 effort would be required to reach that. Whether  
18 that was enough. Whether it was too much.

19 We have a number of years of experience  
20 now. And we have results. I think we have to ask

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 ourselves the question, is the two and a half  
2 percent necessary? Is it enough? Is it  
3 reasonable? Or is one percent enough?

4 I mean, we're actually under one  
5 percent I think. And to reach two and a half  
6 percent, I think you're talking about substantial  
7 effort. I'm not saying that shouldn't be put in.

8 But we have to ask ourselves the  
9 question as to whether or not that additional  
10 amount of review is needed. And if so, how we're  
11 going to achieve it.

12 Or, are we getting enough information  
13 from the present rate of review to assess the  
14 quality of dose reconstruction? Because we've --  
15 the Board may want to say okay, we're willing to  
16 go with a different number.

17 CHAIRMAN MELIUS: And I think the one  
18 is I think we are reassessing the two and a half  
19 percent. I think the question is not just this  
20 part of the process, but is our overall dose

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 reconstruction review approach sufficient?

2 And is it addressing, you know, the  
3 potential for major problems. And you know --

4 MEMBER ZIEMER: Yes, exactly.

5 CHAIRMAN MELIUS: Is it capturing  
6 consistency? Is it capturing all the changes that  
7 constantly go on within, you know, in terms of  
8 procedures and methods and data being available and  
9 so forth?

10 And it is complicated to do that. But  
11 I think we need to -- what I'm trying to say is,  
12 we step back. We look at different options we have  
13 and different ways we might want to do things and  
14 approach that.

15 But the overall package, you know, we  
16 want to be as good as it can be within our available  
17 resources. Now, if we think that, you know, five  
18 percent or, whatever is necessary, then you know,  
19 when we pick up Grady off the floor because, you  
20 know, it increases his workload a great deal and

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1 NIOSH resources.

2 But, you know, again, we need to I think  
3 say that to the Secretary.

4 MEMBER ZIEMER: Exactly.

5 CHAIRMAN MELIUS: I mean, that we need  
6 more resources, or we could, you know -- now, I'm  
7 not thinking we're at the point where we  
8 necessarily need more resources for doing this.

9 But I think we have to, you know, be able  
10 to defend what we've done so far. And I think, I'm  
11 trying to make this as sort of a critical look at  
12 what we've done so far.

13 And how we could improve it. Make it  
14 more efficient. And really address one of our key  
15 functions.

16 And I'm not sure. It's just the  
17 current approach takes up a lot of resources. Both  
18 Board time, and contractor time and NIOSH time and  
19 for money that's associated with that.

20 And so is there a better way, a more

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 efficient way of doing that? And I think yes,  
2 again, we've identified one, maybe we're spending  
3 too much time and resources trying to resolve, you  
4 know, or discussing and reviewing, you know,  
5 negative findings or minor findings.

6 And I think that's legitimate to look  
7 at. But at the same time, it is a Board  
8 responsibility. More than, you know, making an  
9 SEC recommendation is a Board responsibility.  
10 It's not a contractor responsibility. Or it's not  
11 something we, you know, let NIOSH do.

12 MEMBER ZIEMER: Right.

13 CHAIRMAN MELIUS: Yes. So, do that.  
14 So, but maybe we, you know, move on at this point.  
15 And let's start and talk about some of the other  
16 potential parts of doing this.

17 For example, the blind reviews. And  
18 I'd be curious what people's, other people's  
19 assessment of the utility of those.

20 MEMBER KOTELCHUCK: I'd like to hear

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 from -- I'm not sure the Board Members are really  
2 up to date on our -- where we are on the blind  
3 reviews, since we've been doing a lot more  
4 recently.

5 You know, we have 14 blind reviews done  
6 now. I think that's correct, then. So, I would  
7 be -- I'm not sure, Paul, for example, whether you  
8 as a Board Member have -- we presented information  
9 to you about the blind reviews, or enough  
10 information. We certainly talked about them in  
11 Subcommittee.

12 MEMBER ZIEMER: Well, for me, I think  
13 what I would be looking for would be a  
14 recommendation from the Subcommittee to the Board  
15 as to the value of the blind reviews. Whether or  
16 not more are needed and so on.

17 I mean, you guys are looking at them in  
18 detail.

19 MEMBER KOTELCHUCK: Right.

20 MEMBER ZIEMER: I mean, the Board kind

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 of sees it summary-wise. But we need -- those who  
2 are working closely with it, we need, I think, a  
3 recommendation from you as to whether we should  
4 emphasize those more? Do more?

5 Where does the Subcommittee stand on  
6 the usefulness of the blind reviews? Where do  
7 others?

8 MEMBER KOTELCHUCK: Well, should I  
9 respond, Jim?

10 CHAIRMAN MELIUS: Yes.

11 MEMBER KOTELCHUCK: I mean, what has  
12 happened is, we've had long and intense discussions  
13 on a number of these blind reviews. Where at first  
14 there seems to be a disagreement.

15 And then in the discussion it turns out  
16 that there are questions -- often the questions are  
17 not the mechanics of calculating internal dose,  
18 external dose, et cetera. The issues are what  
19 radioactive materials are there?

20 Is it possible that there was depleted

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 uranium being used? And if so, that would, you  
2 know, there could be certain assumptions and  
3 conclusions from that.

4 After we've had the discussions, what  
5 we've found -- what I've -- let me say my  
6 observation. Let me not speak for the Board and  
7 of course Josie is on the line too and should please  
8 come in.

9 My feelings on those is that oftentimes  
10 it's that the folks in SC&A aren't there working  
11 as intimately with the data. And the people,  
12 interviewing people who are at the site.

13 And so oftentimes the NIOSH folks will  
14 give us, if you will, a reality dose. And say no,  
15 no, no, they don't have that.

16 Or, while it may be possible that  
17 something like this happened, it happened and this  
18 is why. And so, we've resolved well all but three  
19 of them.

20 And those three are -- we're working on

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 right now. There was, if you will, Subcommittee  
2 resolution that there was potential agreement.  
3 And that they're recalculating the PoCs.

4 So, we're finding quite good agreement  
5 where the assumptions are the same. There are  
6 times where quite properly SC&A is saying is it  
7 possible that this was being used?

8 Or that this radioactive material had  
9 entered the site briefly and may be around? And  
10 again, I don't know that I'm properly  
11 characterizing SC&A's position on this.

12 But my impression is that we are -- that  
13 the calculations themselves, which are very  
14 important. And I'm extraordinarily happy that  
15 we're doing these. We might want to do more even.

16 But that there's agreement at this  
17 stage between people. But only after discussion.  
18 And discussion about what's going on in the field  
19 if you will. Not with the calculations.

20 Maybe that's the way to characterize

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 it.

2 CHAIRMAN MELIUS: This is Jim. I  
3 would just add to that. I think it's also, at  
4 least, and I've read I think most all of the reports  
5 now. Maybe not some of them.

6 But the ones where there was a  
7 discrepancy, a significant discrepancy, there was  
8 -- I don't know how to characterize this. But I  
9 would say a methodology that was being used by ORAU  
10 that wasn't, you know, that SC&A was not aware of.

11 Or some assumptions that SC&A was not  
12 aware of --

13 MEMBER KOTELCHUCK: Yes.

14 CHAIRMAN MELIUS: About the site. And  
15 I think -- and again, that can be resolved. And  
16 my understanding is that the situations, it was  
17 resolved.

18 I think that the importance of these  
19 blind reviews are twofold. One is sort of what  
20 Dave was talking about, at least as I understood

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1           it, was that how do you interpret what exposures  
2           a person had at a site?

3                         And what needs to be evaluated and so  
4           forth? And again, that may point to some of the  
5           problems with the, you know, Site Profiles or  
6           whatever.

7                         Or, it may point to other documentation  
8           that's not included with the Site Profiles. So,  
9           it's not transparent to the Board or to SC&A.

10                        And then, secondly, are some of these,  
11           you know, calculation procedures that I think are  
12           important for the Board, obviously SC&A to know  
13           about as they're evaluating dose reconstruction.  
14           But also for the Board to, you know, be aware of  
15           in terms of how we oversee and review the dose  
16           reconstruction process.

17                        And again, I think I've said this  
18           before. It's not that I think it's, you know,  
19           these are not sort of deliberately hidden, secret  
20           methodologies or whatever. It's just, you know,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1 dose reconstruction's a complicated process.

2 And these are complicated sites. So,  
3 I don't think it's -- you know, I don't think we  
4 expect everything to be included in, you know, some  
5 sort of technical document or procedure that's, you  
6 know, widely available or whatever available to the  
7 Board, you know, on the website or whatever.

8 But I thought those were there was a  
9 discrepancy found, I thought that was very useful  
10 for understanding how things are being done. And  
11 I think we've always had this issue of, you know,  
12 how do we interpret the facts about a site? And  
13 what people did and so forth.

14 How many we need to do or continue to  
15 do, I don't know. But I think they're -- that they  
16 do have some value in terms of overseeing the  
17 process.

18 MEMBER KOTELCHUCK: Oh, I think --

19 CHAIRMAN MELIUS: But if the process  
20 isn't transparent and reproducible, then there's

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 some problem with it. And if it can't be done  
2 consistently, I think there's a problem with that.

3 I don't know if we've really evaluated  
4 the consistency issue. But certainly the  
5 transparency is, you know, not necessarily there.

6 Again, it doesn't mean that dose  
7 reconstruction is being done wrong. It just  
8 limits our ability to oversee it.

9 MEMBER KOTELCHUCK: I --

10 MEMBER BEACH: This is Josie. Dave,  
11 sorry.

12 MEMBER KOTELCHUCK: Go ahead.

13 MEMBER BEACH: I agree with both of the  
14 -- what you've discussed. I think it's a really  
15 -- blind reviews are important for the reasons that  
16 you both discussed.

17 I don't think they need to be,  
18 definitely not decreased. I'm not sure how many  
19 exactly we're doing at this time number wise.

20 MR. KATZ: Josie, it's Ted. We do a

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 half a dozen a year now. Which was ramped up from  
2 what it was under the old contract.

3 MEMBER BEACH: Okay. Yes.

4 CHAIRMAN MELIUS: I think one thing we  
5 should do before we maybe change that number or  
6 whatever would be to have, this is more work for  
7 Dave, but have the Subcommittee do a presentation  
8 to the Board about their findings.

9 You know, because I don't think the  
10 larger Board Members are aware of it.

11 MEMBER KOTELCHUCK: Yes.

12 CHAIRMAN MELIUS: I think that might be  
13 feasible to do that at one of our Board calls.  
14 Rather than waiting, you know, four or five months  
15 to do it.

16 But, you know, we should think about  
17 that.

18 MEMBER KOTELCHUCK: I would be more  
19 than open. I think the blind reviews are really  
20 of great value. They certainly, for me, give me

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 an enormous amount of confidence in the consistency  
2 of our methods.

3 CHAIRMAN MELIUS: Yes.

4 MEMBER KOTELCHUCK: And I was planning  
5 to have the Board have a discussion of what  
6 constitutes agreements and disagreements.  
7 Because clearly the numbers didn't come in, the  
8 PoCs didn't come in the same.

9 But after discussion we realized that  
10 there were different assumptions. And when the  
11 assumptions were the same, the results were pretty  
12 much the same. And that --

13 MEMBER ZIEMER: Could I ask a question?

14 MEMBER KOTELCHUCK: Sure.

15 MEMBER ZIEMER: Yes. This is for  
16 Dave.

17 MEMBER KOTELCHUCK: Yes?

18 MEMBER ZIEMER: Dave, I don't know if  
19 you have this information, but have you noticed any  
20 difference between blind reviews of older cases

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1       versus newer ones?

2                   I was going through that ORAU document  
3       on their Quality Assurance Program. And it's  
4       clear internally at ORAU that their error rate has  
5       gone down quite a little bit over recent years.

6                   And many of their earlier errors were  
7       based on assumption differences within dose  
8       reconstructors for even given sites. And they  
9       seem to have achieved a better method of assuring  
10      that dose reconstructors who were doing similar or  
11      cases from same sites were using similar or the same  
12      assumptions.

13                  And the implication is that newer dose  
14      reconstructions have a much lower rate of error on  
15      the assumptions themselves. And I wonder if that  
16      shows up for us in our blind reviews as well? Our  
17      newer cases are showing a different level of error,  
18      or perceived error, than older cases. And maybe  
19      we don't know that at this point.

20                  MEMBER KOTELCHUCK: Remember, we only

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 did -- before we did sets, was it 6 through 13, we  
2 only did two blind reviews. So, there's not enough  
3 data -- there's not enough data.

4 MEMBER ZIEMER: There's not enough  
5 data. Okay. Thank you.

6 MEMBER KOTELCHUCK: But, however, you  
7 know, looking at the sets that -- even 6 through  
8 13, I mean, as you suggested, I do see the later  
9 ones that were done. There was a group that was  
10 done for set 17, I believe. The set 17 reviews  
11 seemed to come in quite a bit better than the first  
12 set of six. Which were in the 6 through 13.

13 I must say, I did not look at it  
14 carefully in response to the kind of question that  
15 you asked. But I will.

16 And as you mentioned, it comes to mind  
17 that things are -- we're having fewer disagreements  
18 as we go along to later sets. Which is good.

19 But there's no -- again, as for the  
20 percent of cases reviewed, there's nothing magic

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 about how many we need to do. It's not that we're  
2 going to be able to say that.

3 It's not a statistical question, that  
4 if you do this many, then this is your confidence  
5 interval. I think it's just a matter of saying  
6 that we have to keep monitoring on a regular basis.

7 But I certainly agree that we can say  
8 to the Secretary that we have increased the number  
9 of blind cases reviewed since the first report.  
10 And that those results are very important in  
11 assuring that we have consistency in this -- in the  
12 larger process.

13 MEMBER ZIEMER: But there are sites,  
14 you know, that don't have formal worksheets and  
15 approaches. And maybe more emphasis on those for  
16 the blind reviews would be called for.

17 MEMBER KOTELCHUCK: Yes.

18 MEMBER ZIEMER: Just thinking about  
19 the fact that a lot of sites, the assumptions are  
20 pretty well spelled out.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1                   MEMBER KOTELCHUCK:   And that really  
2 moves to item three I think, does it not?  On to--

3                   CHAIRMAN MELIUS:   Well, let's stay on  
4 this just a second.  I was going to make that  
5 comment.

6                   But I also think it's, you know, we've  
7 done a very limited number of blind reviews.  And  
8 it gives lots more sites than blind reviews.

9                   And, again, I think I concur with Paul's  
10 suggestion that, yes, and that not only do we sort  
11 of need to think about how we target those in terms  
12 of sites.  But also, you know, more specifically,  
13 where there may be sort of less documentation to  
14 rely on.  And therefore, the findings from the  
15 blind review may be more helpful.

16                  MEMBER KOTELCHUCK:   Right.  We speak  
17 to selection because we select only from the sets  
18 that we choose, which have PoCs between 45 and 52  
19 percent.

20                  CHAIRMAN MELIUS:   Yes.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1                   MEMBER KOTELCHUCK: Right? And many  
2 of the others are done on a best estimate -- on a,  
3 excuse me, maximum/minimum basis.

4                   CHAIRMAN MELIUS: Right.

5                   MEMBER KOTELCHUCK: And certainly we  
6 don't blind review those at all. And that seems  
7 to me well-taken and should be done. We should  
8 modify the selection of blind review cases. We  
9 should.

10                  CHAIRMAN MELIUS: So, let's move on to  
11 the -- sort of the number three, which was sort of  
12 the consistency, judgment. I guess, it really  
13 comes back to what you were talking about, also what  
14 are the assumptions that are made by the dose  
15 reconstructor in doing the dose reconstruction and  
16 so forth.

17                  And one thing I was just thinking, when  
18 we're talking about the assumptions now of when we  
19 -- when SC&A and ORAU discuss the -- and NIOSH  
20 discuss the assumptions involved, they reach

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 agreement.

2 But, you know, it's sort of, well, is  
3 that the right agreement? But overall I do think  
4 because there is by nature a lot of judgment  
5 involved in doing these and not all that judgment  
6 can be easily or is necessarily worthwhile to  
7 document.

8 I mean, these are complicated sites.  
9 And their dose reconstructions are difficult to do.  
10 And, you know, there's limited information.  
11 Placing people within these sites and what kind of  
12 work, et cetera that they might have done.

13 And, you know, all the other  
14 complications, we deal with at these sites. But  
15 it would seem to me that one important thing that  
16 we haven't looked at is our -- how are these  
17 assumptions, methodologies that may require more  
18 judgment on the part of the dose reconstructor, how  
19 consistent are they being done?

20 And you know, the QA/QC data from ORAU,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1       you know, it's gotten better. Which is good. But  
2       I think we -- it doesn't mean that we don't need  
3       to look at this. And their QA/QC data may not  
4       capture, you know, all of the issues. And all the  
5       consistency that we might want to do.

6                   And so we need to evaluate that I think.  
7       And I think we've not really been in position or  
8       been able to do that up too now.

9                   And I think that the -- how we target  
10      that I think is we need to sort of think through  
11      and develop, you know. One way of targeting it is,  
12      well, we have a finding where, you know, a  
13      significant finding in a dose reconstruction  
14      review which would indicate something was done, you  
15      know, done wrong.

16                   We agree with SC&A's evaluation and so  
17      forth. Well, you know, how often is that done  
18      wrong? And what is the basis for that error so to  
19      speak?

20                   You know, is it a question of judgment?

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 Is it a question of the underlying documentation  
2 that doesn't, you know, capture maybe what we think  
3 is the appropriate methodology or the appropriate  
4 exposure evaluation that needs to be done for --  
5 at a particular site and so forth.

6 So, to me that's one selection. The  
7 other is sort of the basic, you know, methodology.  
8 And Grady, I don't know if you're still on the line.  
9 Are you?

10 MR. CALHOUN: Yes. I'm on the line.  
11 Can you hear me?

12 CHAIRMAN MELIUS: Yes. This isn't a  
13 quiz or attendance thing. But my question is, what  
14 -- we have the listing of sort of where there's  
15 documentation for doing, you know, so Site Profiles  
16 where there isn't that's being done and so forth.

17 But is there any sort of master mapping  
18 that ORAU may have or NIOSH may have for say dose  
19 reconstruction at a specific site? What  
20 methodologies are used that add up, you know, for

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 doing dose reconstruction at Savannah River or even  
2 a more simple site?

3 Is there sort of a single document that  
4 would sort of list all of the things that a dose  
5 reconstructor would, you know, do? All the  
6 documentation, all the procedures that would be  
7 followed?

8 MR. CALHOUN: For Savannah River, just  
9 to use Savannah River Site as an example.

10 CHAIRMAN MELIUS: Yes, yes.

11 MR. CALHOUN: You know, the starting  
12 point is obviously going to be the Technical Basis  
13 Document. The internal/external X-ray,  
14 environmental section to that.

15 And then the requirements of those  
16 documents are contained within worksheets, which  
17 really help the dose reconstructors not have to  
18 make as many decisions.

19 CHAIRMAN MELIUS: Right.

20 MR. CALHOUN: And those are the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 worksheets that I believe that the DR Subcommittee  
2 folks have finally gotten access to a lot of those  
3 workbooks to them. And that's the main way.

4 Now, there's the other side to that.  
5 You know, just going off the top of my head. Just  
6 one of the sites that doesn't have a Technical Basis  
7 Document.

8 We have guidance written down, they're  
9 not approved documents. But our people are  
10 supposed to write the dose reconstruction in a  
11 detailed enough way that you can tell exactly what  
12 we did.

13 So, I would say that the key really is  
14 getting the information from the Technical Basis  
15 Documents to those workbooks. And those have  
16 evolved.

17 And, you know, through the discussions  
18 that we have during the DR Subcommittee and  
19 evaluating cases, the questions are asked pretty  
20 often like well, what have you done to prevent

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1           there? Because as you said, a lot of these cases  
2           were done a long time ago.

3                         CHAIRMAN MELIUS: Right.

4                         MR. CALHOUN: So, I don't know if Scott  
5           or Ed has anything additional to add to that on the  
6           workbooks.

7                         Evidently not.

8                         CHAIRMAN MELIUS: Okay. Or they can't  
9           find the mute button.

10                        MR. MAHER: Hold on, guys, it's the  
11           mute issue here.

12                        MR. CALHOUN: Right.

13                        MR. MAHER: I would also say that you  
14           need to use the basis for it. The tools, make sure  
15           that whatever can be done consistently is done  
16           consistently. And there's no transcription  
17           errors and all that.

18                        CHAIRMAN MELIUS: Yes.

19                        MR. MAHER: But I also want to point out  
20           that there are lots of interface between the BR,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 who purely deals, who's an independent to do  
2 review. And if they disagree on the  
3 interpretation of a TBD, which has happened at  
4 times, then they work it out, you know, to move on.  
5 Because if they need to elevate it to Scott or Joe,  
6 then they will do that. But, also, Joe and Scott  
7 have the two major bits of BRs. And they meet, you  
8 know, weekly or biweekly to resolve issues.

9 You know, we're interpreting the TBD  
10 this way. We're doing it that way. And to get  
11 those resolved.

12 MR. CALHOUN: And when you say DRs,  
13 you're referring to your dose reconstructors. I'm  
14 not sure everybody knows that.

15 CHAIRMAN MELIUS: Yes.

16 MR. MAHER: Yes, dose reconstructors.  
17 And if it's a crosscutting issue that isn't just  
18 the one slice and it gets rolled up to the objective  
19 management meeting, I have it every other week.  
20 Now, and I also think it's important to point out

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1 that the document on each of these TBDs are DRs for  
2 the most case. And they are the site lead DR.

3 So, it's not like it's a real huge  
4 disconnect between the TBD and what the DR. That  
5 the DRs are actually doing the documents. And  
6 they're also being independently reviewed by a  
7 second DR who's doing claims at that site.

8 So, you know, it's an integrated  
9 process. And you know, we do have some, you know,  
10 differences and interpretation of TBDs. But we  
11 bring them to the surface really quickly.

12 And of course, the reviews that, you  
13 know, Grady's group would do their DRs, and they  
14 would have a different interpretation and send it  
15 back for reconsideration. So, there's a lot of  
16 cross back and forth among, you know, the  
17 production managers, the DRs, PRs, and the document  
18 owners that, you know, work those things out.

19 And that's aside from the training they  
20 go through. Which, you know, all DRs have 40 hours

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 basic training. If they are non-experienced at a  
2 site, then they're given the DRIT, we call a  
3 DRT-status, DR-in-training status.

4 And where they need to work for a DR who  
5 is trained at that site. They must review all the  
6 DRT's DRs before it goes to PR.

7 So, really there's still some  
8 opportunity for inconsistencies. But we are very  
9 concerned with that. And the more tools involved  
10 -- the tools really help with the inconsistencies.

11 MR. KATZ: Alright, can you just  
12 identify yourself, because you're not Scott.

13 MR. MAHER: No, no. I'm Ed Maher. I  
14 have all the dose reconstruction and tool  
15 redevelopment under me.

16 MR. KATZ: Thanks so much.

17 MR. MAHER: Yes.

18 CHAIRMAN MELIUS: My question is, is  
19 that all like -- for an individual site, is that  
20 all documented in one place, what to do? Or sort

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 of how much of this is based on it?

2 MR. MAHER: Well, as far as the  
3 training of the DR, that's documented. I would say  
4 the other things we document it pretty quickly.

5 CHAIRMAN MELIUS: Okay. Okay.  
6 Because I'm just trying to understand, you know,  
7 again, it's not being critical of your process or  
8 whatever.

9 Again, but, you know, sort of from an  
10 outside perspective of how do we identify what  
11 needs to be reviewed and not reviewed? And how do  
12 we assess what you're doing, you know, in terms of  
13 the outcomes in terms of dose reconstruction?

14 But that was very helpful. Thank you.

15 MR. MAHER: Okay.

16 MR. CALHOUN: And this is Grady. And  
17 I just have one more thing to add. It's a little  
18 bit -- there is probably more prescription than it  
19 asks for credit for in the actual TBDs. There's  
20 a lot of "if-then" kind of statements. You know,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 if a person worked here, do this. If they worked  
2 there, find that.

3 So that is in those documents.

4 CHAIRMAN MELIUS: Yes.

5 MR. MAHER: And I think about  
6 methodology. I look at overestimates,  
7 underestimates, maximization techniques. Those  
8 are all -- I look at methodology. And they can  
9 occur at any site with any one claim.

10 CHAIRMAN MELIUS: Right.

11 MR. MAHER: And in some cases it has a  
12 mixture too.

13 CHAIRMAN MELIUS: Yes.

14 MR. MAHER: And I also want to point  
15 out, not to slight Liz because I know she's on the  
16 call, but Liz is our internal dosimetrist,  
17 principal dosimetrist, and she holds meetings  
18 weekly on issues of hey, we have issues of  
19 interpretation of internal dosimetry.

20 So there's other people that also feeds

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 into this now.

2 CHAIRMAN MELIUS: Okay, okay. Thank  
3 you. Does anybody else have questions on that?  
4 Any other things?

5 MEMBER ZIEMER: This is Ziemer. I  
6 have one question for Grady.

7 You know, in some fields such as  
8 laboratory testing, they do what's called split  
9 samples where you send half of each sample to two  
10 different labs. And they analyze it. And you  
11 look at the results.

12 It just occurred to me, do you ever send  
13 the same case to two or more dose reconstructors  
14 to see how their results compare?

15 MR. CALHOUN: Well, we typically -- our  
16 review, once we get the dose reconstruction from  
17 the ORAU Team, it comes over here and one of our  
18 people review it and sign it.

19 And then it goes through another kind  
20 of a higher level of review that just to see if

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1       there's any significant policy changes or anything  
2       like that that have been changed. But we actually  
3       --

4                   MEMBER ZIEMER: No, I understand what  
5       a review is. But I'm sort of asking about -- the  
6       one thing about consistency is between dose  
7       reconstructors. Do they come up with the same  
8       result? From the same case?

9                   MR. CALHOUN: Yes. We actually have a  
10      blind program that we do over here as well.

11                  MEMBER ZIEMER: Okay.

12                  MR. CALHOUN: We haven't finished a lot  
13      of those lately because other items. But we kind  
14      of found that we were running into the same problem  
15      that SC&A was, in that we -- even us, we didn't have  
16      ready access to the tools that were used out there.

17                  And I think we fixed that problem. But  
18      we truly picked at random. And so what happened  
19      was, when you've got an overestimate or an  
20      underestimate and there's somewhat of a

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 discrepancy there, it's not very important.  
2 Because it can be a really big overestimate or a  
3 very little overestimate. And as long as it's  
4 compensable, it's not a big deal.

5 Now, when the SC&A chooses the 48 to 52,  
6 or the Work Group does, that would require a lot  
7 more a review. And to this point, we've not done  
8 that. We've just picked at random.

9 CHAIRMAN MELIUS: Any other questions?

10 Okay.

11 MEMBER KOTELCHUCK: Jim?

12 CHAIRMAN MELIUS: Yes?

13 MEMBER KOTELCHUCK: Okay. Coming  
14 back to something that we talked about before on  
15 the issue of the blind reviews.

16 CHAIRMAN MELIUS: Yes.

17 MEMBER KOTELCHUCK: I had a further  
18 thought if I may come back. By the time we're at  
19 14 blind reviews, it makes some sense to worry about  
20 are we making sure that we've spread the blind

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 reviews out among the appropriate sites.

2 And I just went back to my little table  
3 of the blind -- of the 14 we've done. And I see  
4 we've done a couple of Rocky Flats. We have three  
5 Hanford's that we've done.

6 But that actually -- we should be  
7 thinking now as we accumulate blind reviews, that  
8 we in fact cover a reasonable spectrum of the sites.  
9 And make sure that there are not medium and large  
10 sites that are not being reviewed just because.

11 So, that's something for the future  
12 that we ought to do.

13 CHAIRMAN MELIUS: Yes. And I think  
14 Paul and I were referring to that. But also, in  
15 terms of sites where there's not a Site Profile or,  
16 you know, --

17 MEMBER KOTELCHUCK: Yes. Right.

18 CHAIRMAN MELIUS: Which it's generally  
19 the smaller sites. So, I don't think we want to  
20 exclude them. But we certainly need to be

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1 spreading these out.

2 MEMBER KOTELCHUCK: Right. And I  
3 agree with you on the smaller sites.

4 CHAIRMAN MELIUS: Yes.

5 MEMBER KOTELCHUCK: The smaller sites  
6 need special attention because they're small.

7 CHAIRMAN MELIUS: Okay.

8 MEMBER KOTELCHUCK: Yes. Agreed.

9 CHAIRMAN MELIUS: Okay. Back to sort  
10 of consistency issues. I think what we need to  
11 work out there and I haven't thought it through,  
12 and I don't know if other Work Group Members have  
13 thoughts on how we do this.

14 But it's how we select -- how we target  
15 these. And how many do we have to do to show  
16 consistency or inconsistency? I think it's tricky  
17 and difficult.

18 And that's sort of why I was trying to  
19 get a sense of what, you know, can we get a better  
20 overview of the dose reconstruction methods? And

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 then can we -- that are actually used.

2 And then thinking about what types of  
3 situations we want to target where we think that  
4 consistency is going to be more difficult to  
5 achieve I guess is a way of putting it.

6 And I don't know if anybody has thoughts  
7 on that. That is maybe something we need to think  
8 about and come back to.

9 MEMBER ZIEMER: Well, it's certainly  
10 going to be more of an issue for sites that are not  
11 -- where we don't have the kind of detailed  
12 methodologies.

13 I assume the workbook sites will -- the  
14 sites that have detailed workbooks will inherently  
15 be more consistent in their outcomes. Would that  
16 be a fair statement Dave?

17 MEMBER KOTELCHUCK: I think so. I  
18 think so.

19 MEMBER ZIEMER: So, when we're talking  
20 about consistency here, I guess we're talking about

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 people doing things the same way.

2 And I think we've already identified  
3 that a lot of the inconsistencies hover around  
4 assumptions. So, and the assumptions seem to turn  
5 up more in sites that are not well characterized.

6 I'm sort of thinking off the top of my  
7 head here.

8 If we're going to focus on consistency,  
9 it kind of leads us to sampling certain types of  
10 sites I guess.

11 CHAIRMAN MELIUS: Yes.

12 MEMBER KOTELCHUCK: Right. And this  
13 is a place where I feel that you folks who have been  
14 on the Board from the beginning, not only have a  
15 real advantage, have real knowledge that I lack  
16 just as a relatively new Board Member.

17 I mean, I haven't, you know, I haven't  
18 seen the cases, a lot of the cases where -- I mean,  
19 you have to see a lot of cases to know what's usual  
20 and what's unusual. And what kinds of unusual

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 things may turn up.

2 So, those are -- certainly I feel like  
3 I can use help in trying to identify some of those  
4 sorts of situations.

5 MEMBER ZIEMER: Jim, Ziemer again.

6 CHAIRMAN MELIUS: Well, you bring a  
7 fresh perspective on it, Dave.

8 MEMBER KOTELCHUCK: Well, you know,  
9 but --

10 CHAIRMAN MELIUS: But we'll look at it  
11 that way. We don't want to, you know, pigeonhole  
12 you as the junior Member of the --

13 MEMBER KOTELCHUCK: Well, you know,  
14 you can say different perspective. But I also see  
15 that if you need to have a heart operation, what  
16 do you want to do? Go to a person who's been doing  
17 them for years. Or go to a person who's done half  
18 a dozen and they were all successful.

19 CHAIRMAN MELIUS: Yes.

20 MEMBER KOTELCHUCK: Well, I think I

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 know who I'd choose. So, but in this case for  
2 purely sort of unusual things, oddball things, it's  
3 not -- one might have a new perspective on things  
4 that you have been doing.

5 But you won't have a perspective on  
6 things that you haven't seen done or you haven't  
7 noticed happened in the past.

8 CHAIRMAN MELIUS: Yes. I'll bring up  
9 another issue where I think consistency, you know,  
10 maybe a -- may be problematic. And that's how to  
11 what extent incidents, or, you know, acute  
12 exposures or accidents are taken into account in  
13 dose reconstruction.

14 MEMBER KOTELCHUCK: Yes.

15 CHAIRMAN MELIUS: And now, you know,  
16 we've wrestled with that for a long while. A lot  
17 of it's, you know, issues of documentation and so  
18 forth.

19 But, to me at least, I can think of  
20 instances where it would come up and at least in

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 the public comments on our SEC evaluations and --  
2 or just general public comments on dose  
3 reconstruction where people are -- claimants raise  
4 concerns about, you know, why was this, you know,  
5 why did they not know about and why didn't they  
6 include this in my dose reconstruction and that?

7 So, it may be not on the sort of the  
8 actual dose reconstruction. But what information  
9 is taken into account on the dose reconstruction.

10 Does anybody have any -- is that making  
11 sense, I guess?

12 MEMBER ZIEMER: Well, that makes sense  
13 to me. I think that's an important issue.

14 It also occurred to me, and I know we  
15 don't -- this is a Board responsibility. But it  
16 seems to me, since our contractor invests a lot of  
17 time in the dose reconstruction efforts, that they  
18 may be able to observe or make note of things that  
19 they believe are not consistent. And alert us to  
20 those as well.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 CHAIRMAN MELIUS: Yes.

2 MEMBER KOTELCHUCK: Yes.

3 CHAIRMAN MELIUS: And I'm going to raise  
4 an old issue, which got put to bed by the lawyers  
5 many years ago. But I think it's another somewhat  
6 related to incidents.

7 But I think the overall is how the  
8 interviews are evaluated and incorporated into the  
9 dose reconstruction process. And Dave, since  
10 you're new, we had a long discussion and sort of  
11 internal disagreements within the Board and with  
12 NIOSH about our ability as part of the blind reviews  
13 to go out and re-interview the claimants.

14 And it just got everyone concerned  
15 about doing that. And so, we decided to -- the  
16 Board decided not to -- not sort of hold that in  
17 abeyance and whether we need to go, you know, in  
18 some future time consider that or not.

19 And I just want to mention it. And I  
20 think a lot of that has to do with -- now the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 documentation is better. And at least individual  
2 reviews, dose reconstructions that are done, I see  
3 a lot more reference to the interviews and  
4 evaluation of them. That I think is helpful.

5 But I think in the area of incidents is  
6 where it's more problematic. And some of that's  
7 just inherent in the fact that, you know, the  
8 interviews were often with survivors and people  
9 that really don't know what their spouse or father  
10 or mother did at the -- in working at the site.

11 At any level of detail because there was  
12 secrecy, et cetera, in time.

13 And one of the things we can do is, I  
14 have no problems with, is suggesting that SC&A, you  
15 know, prepare a short report suggesting particular  
16 areas where there may be issues with, you know,  
17 consistency that we could, you know, should be  
18 focusing on.

19 Does that make sense to the other Work  
20 Group Members?

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1                   MEMBER BEACH:    Yes, Jim.    This is  
2                   Josie.    That makes perfect sense.    And I think  
3                   your comment on the interviews, it's very valuable  
4                   to interview workers.

5                   And I agree, you have to have the  
6                   interviews with the workers and not necessarily  
7                   survivors.    But that's an important key.

8                   MEMBER KOTELCHUCK:    Yes.    I agree  
9                   also.    I    think    both    the    incidents,  
10                  accidents/incidents recording and what we do with  
11                  the CATI reviews is important.

12                  And I agree with Josie that the  
13                  interviews the survivors, I don't think what we --  
14                  if that's the only option we have, of course we do  
15                  them.

16                  But I must say, they are much less  
17                  helpful than interviews with individual workers.

18                  MR. MAHER:    Yes.    This is Ed Maher.  
19                  Can I make a comment addressing that?

20                  CHAIRMAN MELIUS:    Sure.    Go ahead Ed.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1                   MR. MAHER: All right. We had one  
2 claim where we interviewed the survivor. And the  
3 survivor was a technical person.

4                   And she mentioned that this individual  
5 was involved in the SL-1 accident. And of course  
6 those records were not given to us by the site. We  
7 had to go hunting for them.

8                   And sure enough, she was exactly right.  
9 So, we don't treat survivor interviews lightly.  
10 Sometimes they're spot on.

11                  CHAIRMAN MELIUS: Yes. No, it's a  
12 good point. And I think usually it's the opposite  
13 error is that they just don't -- aren't aware of  
14 that.

15                  Or they're -- the information they have  
16 about an incident or an exposure is so vague it's,  
17 you know, -- well, you know, by the passage of time,  
18 well it was 20 years ago or whatever.

19                  And unless you, you know, it's hard to  
20 evaluate that unless you can link it to a known

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 incident or, you know, some documentation of that.

2 And I think we know from at least some of the sites  
3 that the documentation is poor on those incidents.

4 MEMBER KOTELCHUCK: Well, we have an  
5 obligation no matter what. You know, no matter how  
6 useful or not useful they are, we have an obligation  
7 to interview those folks.

8 And it is well taken that sometimes it  
9 provides really good information that we don't  
10 otherwise have. But whether or not we get good  
11 information, it's up to us to evaluate it.

12 But we need to call them.

13 CHAIRMAN MELIUS: Right. Yes.

14 MR. MAHER: And let me also add that,  
15 you know, the quality of a survivor interview, the  
16 technical quality is not going to be --

17 CHAIRMAN MELIUS: Yes.

18 MR. MAHER: Except in rare instances.  
19 But I would also say in the past, and I'm talking  
20 about ten years ago, if in the CATI we saw a

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 reference to an incident, and we saw them all the  
2 time saying, I was contaminated with skin counts  
3 through such and such.

4 You know, we will attempt to  
5 reconstruct it. Now if the information was not  
6 relevant to dose reconstruction, a lot of people  
7 talk about chemical exposures --

8 CHAIRMAN MELIUS: Right.

9 MR. MAHER: We would not mention it.  
10 And that was probably a mistake. Because we should  
11 at least mention it in the pre-narrative of the DR  
12 report. And say it has no bearing on the dose  
13 reconstruction.

14 Now we do that more consistently.

15 CHAIRMAN MELIUS: Yes. Yes. No, I  
16 think the documentation that you've done on the  
17 incidences and based on the interviews has been  
18 much better.

19 Any other questions on the consistency  
20 issue?

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1                   For our next steps, what I was going to  
2 suggest one is the -- I think we gave two  
3 assignments for Dave I think it was.

4                   And I think one is -- well, first off  
5 for Dave is the presentation on summary of the blind  
6 reviews that have been completed so far for an  
7 upcoming either Board meeting or a Board call.

8                   And leave it up to Dave to decide, you  
9 know, what's appropriate timing and so forth on  
10 that. We'd do that.

11                   And then I think we probably need to  
12 think more, you know, and Dave may want to talk to  
13 the other Members of the Dose Reconstruction Review  
14 Committee about, you know, this issue of how do we  
15 handle -- what's the best way of handling and  
16 prioritizing the time and resources available to  
17 that Committee in terms of doing reviews?

18                   And we probably should come back and for  
19 this group is to have some discussion which we  
20 really haven't done today on, you know, sort of

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 selection of the -- of cases. And how we want to  
2 approach that.

3 So we can make a recommendation.  
4 Though I don't think that recommendation is going  
5 to be overly prescriptive simply because I think  
6 really the Dose Reconstruction Review Committee  
7 sort of needs to do that on an ongoing basis.

8 But I think if we can put some framework  
9 that the whole Board can agree on, I think that  
10 would be helpful. Then I think we need to come back  
11 and talk about the -- sort of think about how we  
12 -- consistency, what information would be useful.

13 And I think we're asking SC&A to, you  
14 know, give us a short report that would, you know,  
15 recommend certain -- where they think that the  
16 consistency issue -- consistency maybe an issue  
17 that, you know, in terms of how we select and what  
18 we should focus on.

19 Am I missing anything?

20 MEMBER ZIEMER: I think that covers it

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 pretty well.

2 CHAIRMAN MELIUS: Okay. Any further  
3 thoughts?

4 MEMBER KOTELCHUCK: Sounds good.

5 CHAIRMAN MELIUS: Okay. At least for  
6 some of us it's getting towards lunch time. So,  
7 we get a little -- we slow down a little bit.

8 MEMBER KOTELCHUCK: Okay.

9 CHAIRMAN MELIUS: But if you have to go  
10 get another cup of coffee or --

11 MEMBER BEACH: Yes.

12 MEMBER KOTELCHUCK: Very good.

13 CHAIRMAN MELIUS: Early morning.

14 But, anyway. So, I thank everybody for their time.

15 Ted, do you have any?

16 MR. KATZ: No, I don't. But thanks.

17 That was a good meeting.

18 CHAIRMAN MELIUS: Yes. Final word.

19 And thank everybody. And, oh, I know what is the  
20 final.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1                   What I will do, they're probably  
2 overdue now, because -- but I will prepare a set  
3 aside. We've set aside 45 minutes for the Board  
4 meeting I think on the agenda.

5                   And I will just sort of present an  
6 update on what we've been discussing sort of under  
7 these general categories. If that's reasonable.

8                   And then, I mean, I think what we really  
9 want to do is generate, you know, more Board input  
10 and discussion. And hopefully we can. And then  
11 when we get the report back from SC&A, I'll figure  
12 out, we'll hold another meeting. And by that time,  
13 I think people will have more of a chance to review  
14 the -- their recent report that they sent us last  
15 week.

16                   And that may generate some other  
17 discussion also.

18                   MEMBER KOTELCHUCK: Very good.

19                   CHAIRMAN MELIUS: Okay. Thank you  
20 all.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1 MEMBER KOTELCHUCK: Thank you.

2 CHAIRMAN MELIUS: And if we don't talk  
3 to you, we'll see you in Oakland --

4 MEMBER KOTELCHUCK: Very good.

5 MEMBER BEACH: Okay.

6 CHAIRMAN MELIUS: In a couple of weeks.  
7 And actually some of you in Cincinnati next week.

8 MEMBER BEACH: Oh, that's right. See  
9 you Thursday.

10 CHAIRMAN MELIUS: We have the Idaho.

11 MEMBER BEACH: Yes, we do.

12 CHAIRMAN MELIUS: Tuesday. Tuesday,  
13 not Thursday.

14 MEMBER BEACH: Yes. See you next  
15 week.

16 CHAIRMAN MELIUS: Okay. Take care.  
17 Bye-bye.

18 MEMBER KOTELCHUCK: Bye-bye, all.

19 (Whereupon, the above-entitled matter  
20 was concluded at 11:52 a.m.)

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701